{"id":685771,"date":"2024-01-25T14:24:02","date_gmt":"2024-01-25T14:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685771"},"modified":"2024-01-25T14:24:02","modified_gmt":"2024-01-25T14:24:02","slug":"spinraza-nusinersen-for-spinal-muscular-atrophy-market-size-and-share-analysis-and-competitive-landscape-by-delveinsight-key-players-biogen-and-ionis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/spinraza-nusinersen-for-spinal-muscular-atrophy-market-size-and-share-analysis-and-competitive-landscape-by-delveinsight-key-players-biogen-and-ionis-pharmaceuticals_685771.html","title":{"rendered":"Spinraza (Nusinersen) for Spinal Muscular Atrophy: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Biogen and Ionis Pharmaceuticals"},"content":{"rendered":"
\n
\"Spinraza<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight has recently published a report on \u201cSpinraza (Nusinersen) Market Forecast Report\u201d providing an in-depth analysis of the Spinraza (Nusinersen) market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/div>\n

The comprehensive report provides an analysis of Spinraza (Nusinersen) market potential and market share analysis in the Spinal Muscular Atrophy therapeutics space across the 7MM from 2019 to 2032. The report also helps you to understand the Spinraza (Nusinersen) clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.<\/em><\/p>\n

Spinraza (Nusinersen) Drug Insight<\/strong><\/a><\/p>\n

SPINRAZA is being developed globally for the treatment of Spinal Muscular Atrophy (SMA). SPINRAZA is an antisense oligonucleotide (ASO) that is designed to treat Spinal Muscular Atrophy caused by mutations in the chromosome 5q that leads to SMN protein deficiency. SPINRAZA alters the splicing of SMN2 pre-mRNA in order to increase the production of full-length Spinal Muscular Atrophy protein. ASOs are short synthetic strings of nucleotides designed to selectively bind to target RNA and regulate gene expression. Through use of this technology, SPINRAZA has the potential to increase the amount of full-length SMN protein in patients with Spinal Muscular Atrophy.<\/p>\n

Spinraza (Nusinersen) – Regulatory Development<\/strong><\/p>\n

On December 23, 2016, the United States Food and Drug Administration (FDA)<\/strong> granted approval for SPINRAZA (nusinersen)<\/strong>, marking a historic milestone as the first drug sanctioned for the treatment of spinal muscular atrophy (SMA) in both pediatric and adult patients. The approved dosage for SPINRAZA injection stands at 12 mg (5 mL) per intrathecal administration.<\/p>\n

The commencement of SPINRAZA treatment involves a loading phase consisting of four doses. The first three doses are administered at 14-day intervals, followed by the fourth dose, administered 30 days after the third loading dose. Subsequently, a maintenance dose of SPINRAZA should be administered once every four months to sustain therapeutic benefits.<\/p>\n

The intrathecal administration of SPINRAZA, conducted over a period of 1 to 3 minutes, requires the expertise of healthcare professionals experienced in performing lumbar punctures. The drug’s administration regimen emphasizes the significance of precise medical supervision to ensure optimal efficacy and patient safety.<\/p>\n

Stay ahead of the competition by leveraging key insights and evolving trends in the market @ <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/spinraza-nusinersen-drug-insight-market-forecast<\/a><\/strong><\/p>\n

Key Highlights of the Spinraza (Nusinersen) Market Report<\/strong><\/p>\n